All Trials

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with nonmetastatic, locally advanced pancreatic adenocarcinoma after 4–6 months of induction chemotherapy (FOLFIRINOX, NALIRIFOX, or gemcitabine/nab-paclitaxel), ECOG 0–2, and planned non-operative management receive hypofractionated radiotherapy with or without oral peposertib. Peposertib is a selective DNA-PK inhibitor and radiosensitizer given concurrently for 14 days to enhance radiation efficacy; phase 2 randomizes against placebo.

ClinicalTrials.gov ID: NCT04172532

Phase 1 Clinical Trial of Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced, unresectable pancreatic ductal adenocarcinoma (ECOG 0–2) after ≥4 months of multiagent chemotherapy and no metastases undergo surgical irreversible electroporation (IRE) with concurrent intratumoral mitazalimab, an agonistic CD40 monoclonal antibody aimed at activating dendritic cells and enhancing antitumor T-cell priming. Excludes prior pancreatic radiation, prior CD40 therapy, active autoimmune disease, implanted cardiac devices/metal, or tumors >4 cm or not amenable to complete IRE.

ClinicalTrials.gov ID: NCT06205849

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable, MTAP‑deleted pancreatic ductal adenocarcinoma (measurable disease, adequate organs; no prior PRMT5/MAT2A inhibitors and, for the RAS combo, no prior MAPK/KRAS inhibitors) receive AMG 193, an oral MTA‑cooperative PRMT5 inhibitor exploiting MTAP synthetic lethality, combined with either gemcitabine/nab‑paclitaxel, modified FOLFIRINOX, or with RMC‑6236, an oral RAS(ON) tri‑complex inhibitor for RAS‑mutant cohorts. The study explores dose, safety, PK, and preliminary efficacy with expansion in defined PDAC cohorts.

ClinicalTrials.gov ID: NCT06360354

A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated locally advanced unresectable or metastatic exocrine pancreatic adenocarcinoma (ECOG 0–1) receive NALIRIFOX plus oral onvansertib, a selective PLK1 inhibitor given days 1–5 each 14-day cycle. Key exclusions include significant cardiac risk/QTc prolongation, uncontrolled infection, untreated brain mets, GI absorption issues, strong CYP3A4/CYP2C19 modulators, and clinically significant effusions.

ClinicalTrials.gov ID: NCT06736717

A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Single-arm study of oral memantine, a noncompetitive NMDA receptor antagonist, as monotherapy for adults with unresectable, locally advanced or metastatic HCC and decompensated liver function (Child-Pugh ≥ B7), ECOG 0–2, who are not candidates for intensive systemic therapy. Includes previously untreated patients with measurable disease; key exclusions include Child-Pugh A, rare HCC variants, significant recent CV events, and active CNS metastases.

ClinicalTrials.gov ID: NCT06007846

A Phase Ib Study of Cryoablation and Pressure-enabled Hepatic Arterial Infusion of Class C Toll-like Receptor 9 Agonist SD-101 in Combination with Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced/metastatic or unresectable HCC, systemic-therapy–naive for advanced disease (ECOG 0–1, Child-Pugh A–B7), undergo focal hepatic lesion cryoablation plus pressure-enabled hepatic arterial infusion of SD-101 (nelitolimod, a class C TLR9 agonist activating pDCs/type I IFN signaling) followed 7–10 days later by STRIDE: one priming dose of tremelimumab and durvalumab every 4 weeks. Requires at least one hepatic lesion ≥3 cm away from critical structures; excludes active autoimmune disease requiring immunosuppression, uncontrolled comorbidities, and active CNS disease.

ClinicalTrials.gov ID: NCT06710223

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic hepatocellular carcinoma, enriched for β‑catenin (CTNNB1)–mutated disease (Phase II requires CLIA-confirmed mutation, Child-Pugh A, ECOG 0–2, prior ICI), randomized to cabozantinib alone vs cabozantinib plus sapanisertib (TAK‑228), an oral ATP-competitive mTORC1/2 inhibitor. Allows controlled HBV/HCV and treated/stable brain mets; excludes prior cabozantinib and strong CYP3A4 inhibitors.

ClinicalTrials.gov ID: NCT06811116

Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with well-differentiated, liver-dominant metastatic neuroendocrine tumors (ECOG 0–1) and documented intrahepatic progression receive intra-arterial tirapazamine immediately followed by conventional TAE (Lipiodol/Gelfoam). Tirapazamine is a hypoxia-activated prodrug that generates DNA-damaging radicals and functions as a tumor-selective topoisomerase II poison under low oxygen, aiming to potentiate embolization-induced hypoxia.

ClinicalTrials.gov ID: NCT02174549

A Phase 1-2 Study of ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced, unresectable HCC (ECOG 0–1, Child-Pugh A) after at least one prior systemic therapy receive nivolumab plus ABX196, an intramuscular synthetic α-galactosylceramide analog that activates iNKT cells via CD1d to augment antitumor immunity. Excludes main portal vein/IVC/cardiac invasion, significant recent variceal bleeding, active autoimmune disease requiring treatment, prior transplant, and significant decompensation; controlled HBV allowed.

ClinicalTrials.gov ID: NCT03897543

A Phase Ib/II, Dose Escalation and Dose Expansion Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma (HCC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Previously untreated adults with unresectable/advanced HCC (Child-Pugh A, BCLC B not eligible for liver-directed therapy or C, ECOG 0–1) receive valemetostat (oral dual EZH1/EZH2 inhibitor) combined with atezolizumab and bevacizumab on 21-day cycles. Excludes high bleeding risk (e.g., untreated/high-risk varices), active autoimmune disease requiring systemic therapy, uncontrolled HBV/HCV, and prior EZH inhibitor exposure.

ClinicalTrials.gov ID: NCT06294548